{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:17:32Z","timestamp":1791357452081,"version":"4.3.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009045","name":"Jagiellonian University Medical College","doi-asserted-by":"publisher","award":["K\/ZDS\/006133"],"award-info":[{"award-number":["K\/ZDS\/006133"]}],"id":[{"id":"10.13039\/100009045","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Behavioural Brain Research"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.bbr.2018.10.004","type":"journal-article","created":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T12:25:04Z","timestamp":1539087904000},"page":"9-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Novel antagonists of 5-HT6 and\/or 5-HT7 receptors affect the brain monoamines metabolism and enhance the anti-immobility activity of different antidepressants in rats"],"prefix":"10.1016","volume":"359","author":[{"given":"Anna","family":"Partyka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Jastrz\u0119bska-Wi\u0119sek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucyna","family":"Antkiewicz-Michaluk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerzy","family":"Michaluk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"W\u0105sik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Canale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Zajdel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Ko\u0142aczkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Weso\u0142owska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbr.2018.10.004_bib0005","series-title":"World Federation For Mental Health (WFMH), Depression: A Global Crisis, World Ment. Heal. Day","first-page":"32","year":"2012"},{"key":"10.1016\/j.bbr.2018.10.004_bib0010","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1517\/13543784.2014.985784","article-title":"Criticisms of drugs in early development for the treatment of depression: what can be improved?","volume":"24","author":"Wang","year":"2015","journal-title":"Expert Opin. Investig. Drugs."},{"key":"10.1016\/j.bbr.2018.10.004_bib0015","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.pharmthera.2005.11.006","article-title":"Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application","volume":"110","author":"Millan","year":"2006","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bbr.2018.10.004_bib0020","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.euroneuro.2013.04.013","article-title":"Developments in the field of antidepressants, where do we go now?","volume":"25","author":"Artigas","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.bbr.2018.10.004_bib0025","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1177\/0897190011426972","article-title":"Targeting treatment-resistant depression","volume":"24","author":"Mathys","year":"2011","journal-title":"J. Pharm. Pract."},{"key":"10.1016\/j.bbr.2018.10.004_bib0030","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/npp.2011.13","article-title":"Pharmacological blockade of 5-HT7 receptors as a putative fast acting antidepressant strategy","volume":"36","author":"Mnie-Filali","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbr.2018.10.004_bib0035","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.neures.2010.04.003","article-title":"Serotonin 6 receptor gene and mood disorders: Case\u2013control study and meta-analysis","volume":"67","author":"Fukuo","year":"2010","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.bbr.2018.10.004_bib0040","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/B978-0-12-385902-0.00003-6","article-title":"Behavioral pharmacology: potential antidepressant and anxiolytic properties","volume":"96","author":"Weso\u0142owska","year":"2011","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.bbr.2018.10.004_bib0045","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00213-009-1626-0","article-title":"The 5-HT7 receptor and disorders of the nervous system: an overview","volume":"206","author":"Hedlund","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.bbr.2018.10.004_bib0050","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0022-3565(25)38596-4","article-title":"Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors","volume":"268","author":"Roth","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbr.2018.10.004_bib0055","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0165-6147(97)01043-2","article-title":"The 5-HT7 receptor: orphan found","volume":"18","author":"Eglen","year":"1997","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bbr.2018.10.004_bib0060","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/sj.bjp.0703458","article-title":"Characterization of [(125)I]-SB-258585 binding to human recombinant and native 5-HT(6) receptors in rat, pig and human brain tissue","volume":"130","author":"Hirst","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbr.2018.10.004_bib0065","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1515\/revneuro-2014-0001","article-title":"Memory formation and memory alterations: 5-HT6and 5-HT7receptors, novel alternative","volume":"25","author":"Meneses","year":"2014","journal-title":"Rev. Neurosci."},{"key":"10.1016\/j.bbr.2018.10.004_bib0070","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/B978-0-12-385902-0.00002-4","article-title":"5-HT6 receptor memory and amnesia: behavioral pharmacology--learning and memory processes","volume":"96","author":"Meneses","year":"2011","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.bbr.2018.10.004_bib0075","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.bbr.2007.12.012","article-title":"5-HT7 receptors in the modulation of cognitive processes","volume":"195","author":"Cifariello","year":"2008","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.bbr.2018.10.004_bib0080","doi-asserted-by":"crossref","DOI":"10.1021\/acsmedchemlett.6b00056","article-title":"N1-azinylsulfonyl-1H-indoles: 5-HT6 receptor antagonists with procognitive and antidepressant-like properties","volume":"7","author":"Zajdel","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bbr.2018.10.004_bib0085","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.bmc.2015.11.041","article-title":"N-alkylated arylsulfonamides of (aryloxy)ethyl piperidines: 5-HT7receptor selectivity versus multireceptor profile","volume":"24","author":"Canale","year":"2016","journal-title":"Bioorganic Med. Chem."},{"key":"10.1016\/j.bbr.2018.10.004_bib0090","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00210-014-0966-4","article-title":"Antipsychotic, antidepressant, and cognitive-impairment properties of antipsychotics: rat profile and implications for behavioral and psychological symptoms of dementia","volume":"387","author":"Ko\u0142aczkowski","year":"2014","journal-title":"Naunyn. Schmiedebergs. Arch. Pharmacol."},{"key":"10.1016\/j.bbr.2018.10.004_bib0095","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1016\/j.bmc.2017.03.057","article-title":"Novel 5-HT7R antagonists, arylsulfonamide derivatives of (aryloxy)propyl piperidines: add-on effect to the antidepressant activity of SSRI and DRI, and pro-cognitive profile","volume":"25","author":"Canale","year":"2017","journal-title":"Bioorganic Med. Chem."},{"key":"10.1016\/j.bbr.2018.10.004_bib0100","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0014-2999(78)90118-8","article-title":"Behavioural despair in rats: a new model sensitive to antidepressant treatments","volume":"47","author":"Porsolt","year":"1978","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbr.2018.10.004_bib0105","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/bph.12509","article-title":"ADN-1184 a monoaminergic ligand with 5-HT6\/7 receptor antagonist activity: pharmacological profile and potential therapeutic utility","volume":"171","author":"Ko\u0142aczkowski","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbr.2018.10.004_bib0110","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.neuroscience.2015.09.064","article-title":"Distribution of serotonin receptor 5-HT6 mRNA in rat neuronal subpopulations: a double in situ hybridization study","volume":"310","author":"Helboe","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.bbr.2018.10.004_bib0115","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/YIC.0000000000000023","article-title":"A comparative review of escitalopram, paroxetine, and sertraline: are they all alike?","volume":"29","author":"Sanchez","year":"2014","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.bbr.2018.10.004_bib0120","series-title":"Enhancement of the Anti-Immobility Action of Antidepressants by a Selective 5-HT7 Receptor Antagonist in the Forced Swimming Test in Mice","author":"Weso\u0142owska","year":"2007"},{"key":"10.1016\/j.bbr.2018.10.004_bib0125","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1124\/jpet.107.119404","article-title":"Selective blockade of 5-hydroxytryptamine (5-HT)7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodents","volume":"321","author":"Bonaventure","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbr.2018.10.004_bib0130","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1254\/jphs.08201SC","article-title":"Potentiation of the antidepressant-like effect of fluoxetine by aripiprazole in the mouse tail suspension test","volume":"108","author":"Kamei","year":"2008","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.bbr.2018.10.004_bib0135","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.bbr.2010.01.022","article-title":"The 5-HT(7) receptor as a mediator and modulator of antidepressant-like behavior","volume":"209","author":"Sarkisyan","year":"2010","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.bbr.2018.10.004_bib0140","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.physbeh.2012.12.009","article-title":"The effects of combining serotonin reuptake inhibition and 5-HT7receptor blockade on circadian rhythm regulation in rodents","volume":"110\u2013111","author":"Westrich","year":"2013","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.bbr.2018.10.004_bib0145","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/S0006-3223(99)00291-7","article-title":"Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor","volume":"47","author":"Wong","year":"2000","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bbr.2018.10.004_bib0150","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/syn.10288","article-title":"5-HT6 receptor antagonist SB-271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex","volume":"51","author":"Lacroix","year":"2004","journal-title":"Synapse."},{"key":"10.1016\/j.bbr.2018.10.004_bib0155","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/0306-4522(94)00439-C","article-title":"Localization of serotonin subtype 6 receptor messenger RNA in the rat brain by in situ hybridization histochemistry","volume":"64","author":"Ward","year":"1995","journal-title":"Neuroscience"},{"key":"10.1016\/j.bbr.2018.10.004_bib0160","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/(SICI)1098-2396(199607)23:3<164::AID-SYN5>3.0.CO;2-6","article-title":"Quantitative RT-PCR distribution of serotonin 5-HT6 receptor mRNA in the central nervous system of control or 5,7-dihydroxytryptamine-treated rats","volume":"23","author":"G\u00e9rard","year":"1996","journal-title":"Synapse"},{"key":"10.1016\/j.bbr.2018.10.004_bib0165","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/sj.bjp.0707253","article-title":"Tricyclic antidepressant pharmacology and therapeutic drug interactions updated","volume":"151","author":"Gillman","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbr.2018.10.004_bib0170","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2165\/1159616-S0-000000000-00000","article-title":"The efficacy and tolerability of bupropion in the treatment of major depressive disorder","volume":"31","author":"Moreira","year":"2011","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.bbr.2018.10.004_bib0175","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0028-3908(01)00165-4","article-title":"5-HT(6) receptor antagonism potentiates the behavioral and neurochemical effects of amphetamine but not cocaine","volume":"42","author":"Frantz","year":"2002","journal-title":"Neuropharmacology."},{"key":"10.1016\/j.bbr.2018.10.004_bib0180","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.pbb.2004.03.017","article-title":"Modulation of the stimulus effects of (+)amphetamine by the 5-HT6 antagonist MS-245","volume":"78","author":"Pullagurla","year":"2004","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.bbr.2018.10.004_bib0185","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0361-9230(02)00967-X","article-title":"Potentiation of amphetamine-induced changes in dopamine and 5-HT by a 5-HT6 receptor antagonist","volume":"59","author":"Dawson","year":"2003","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.bbr.2018.10.004_bib0190","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.brainres.2006.11.060","article-title":"5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus","volume":"1134","author":"Li","year":"2007","journal-title":"Brain Res"},{"key":"10.1016\/j.bbr.2018.10.004_bib0195","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejphar.2007.12.013","article-title":"The selective 5-HT6 receptor antagonist SB-399885 enhances anti-immobility action of antidepressants in rats","volume":"582","author":"Weso\u0142owska","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbr.2018.10.004_bib0200","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/syn.20034","article-title":"Neurochemical interaction between dopaminergic and noradrenergic neurons in the medial prefrontal cortex","volume":"53","author":"Pan","year":"2004","journal-title":"Synapse"},{"key":"10.1016\/j.bbr.2018.10.004_bib0205","first-page":"664","article-title":"Study into a possible mechanism responsible for the antidepressant-like activity of the selective 5-HT6 receptor antagonist SB-399885 in rats","volume":"59","author":"Weso\u0142owska","year":"2007","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.bbr.2018.10.004_bib0210","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/sj.bjp.0705328","article-title":"Evidence that central 5-HT 2A and 5-HT 2B\/C receptors regulate 5-HT cell firing in the dorsal raphe nucleus of the anaesthetised rat","volume":"139","author":"Boothman","year":"2003","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbr.2018.10.004_bib0215","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.neuropharm.2005.11.020","article-title":"Investigation of the SSRI augmentation properties of 5-HT2 receptor antagonists using in vivo microdialysis","volume":"50","author":"Boothman","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbr.2018.10.004_bib0220","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1038\/sj.npp.1300762","article-title":"The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine","volume":"30","author":"Marek","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbr.2018.10.004_bib0225","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0165-0327(11)70003-9","article-title":"Neurobiological bases and clinical aspects of the use of aripiprazole in treatment-resistant major depressive disorder","volume":"128","author":"Blier","year":"2011","journal-title":"J. Affect. Disord."}],"container-title":["Behavioural Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432818310015?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432818310015?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T19:09:39Z","timestamp":1775243379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166432818310015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":45,"alternative-id":["S0166432818310015"],"URL":"https:\/\/doi.org\/10.1016\/j.bbr.2018.10.004","relation":{},"ISSN":["0166-4328"],"issn-type":[{"value":"0166-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel antagonists of 5-HT6 and\/or 5-HT7 receptors affect the brain monoamines metabolism and enhance the anti-immobility activity of different antidepressants in rats","name":"articletitle","label":"Article Title"},{"value":"Behavioural Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbr.2018.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}